Because human carriage of pneumococcus usually results in improved immunity to future infections without any development of disease, Stephen Gordon of the Liverpool School of Tropical Medicine in the United Kingdom will use an intranasal inoculation with a safe strain of the bacteria to study the mechanisms of mucosal immunity in the lungs and to explore the potential for a vaccine based on his findings. In this project’s Phase I research, Gordon successfully demonstrated that human carriage of pneumococcus provides improved immunity to future infections, and that nasal inoculation immunizes the lungs against the pathogen. In Phase II, Gordon will work to assess the reproducibility of his model to ensure its robustness as a candidate for a pneumococcal vaccine.
Grant ID
OPP1035281
Show on Hub
Off
Show on Spoke
Off
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
998437.00
Funding Currency
USD
Funding Amount (in USD)
998437.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
998437.00
Initial Grant
Co-Funded
False